Back to top

Image: Bigstock

Top Ranked Value Stocks to Buy for December 7th

Read MoreHide Full Article

Here are three stocks with buy rank and strong value characteristics for investors to consider today, December 7th:

Innoviva, Inc. (INVA - Free Report) : This pharmaceuticals company has a Zacks Rank #1 (Strong Buy), and seen the Zacks Consensus Estimate for its current year earnings rising 24.3% over the last 60 days.

 

Innoviva, Inc. Price and Consensus

Innoviva, Inc. Price and Consensus

Innoviva, Inc. price-consensus-chart | Innoviva, Inc. Quote

 

Innoviva has a price-to-earnings ratio (P/E) of 4.78, compared with 14.80 for the industry. The company possesses a Value Score of A.

 

Innoviva, Inc. PE Ratio (TTM)

Innoviva, Inc. PE Ratio (TTM)

Innoviva, Inc. pe-ratio-ttm | Innoviva, Inc. Quote

 

Capital Product Partners L.P. (CPLP - Free Report) : This shipping company that provides marine transportation services has a Zacks Rank #2 (Buy), and seen the Zacks Consensus Estimate for its current year earnings rising 9.6% over the last 60 days.

 

Capital Product Partners has a price-to-earnings ratio (P/E) of 4.67, compared with 9.40 for the industry. The company possesses a Value Score of A.

 

360 DigiTech, Inc. (QFIN - Free Report) : This data driven, technology empowered digital platform has a Zacks Rank #2, and seen the Zacks Consensus Estimate for its current year earnings rising 19% over the last 60 days.

 

360 DigiTech has a price-to-earnings ratio (P/E) of 3.56, compared with 30.00 for the industry. The company possesses a Value Score of A.

360 DigiTech, Inc. PE Ratio (TTM)

360 DigiTech, Inc. Sponsored ADR PE Ratio (TTM)

360 DigiTech, Inc. pe-ratio-ttm | 360 DigiTech, Inc. Quote

 

See the full list of top ranked stocks here.

Learn more about the Value score and how it is calculated here.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Innoviva, Inc. (INVA) - free report >>

Capital Product Partners L.P. (CPLP) - free report >>

360 DigiTech, Inc. Sponsored ADR (QFIN) - free report >>